FibroGen Announces Appointment Of Michael Kauffman, M.D., Ph.D. To Board Of Directors

FibroGen, Inc. announced that Dr. Michael Kauffman has joined its Board of Directors, effective June 4, 2025. Dr. Kauffman brings years of experience in the biopharmaceutical industry, including leadership roles in drug development and executive management. His appointment is expected to strengthen FibroGen’s strategic direction and support the company’s mission to develop innovative treatments for patients around the world.

James Schoeneck, chairman of the board of directors of FibroGen, stated, “Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board. His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael’s deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers.”

Dr. Kauffmam said, “FibroGen has differentiated potential first-in-class assets and the company is positioning itself for a significant turnaround over the next several years. It is an honor to join the board at this exciting time for the company, and I look forward to contributing to the company’s future success.”